Cytek Biosciences Q2 Revenue Dips, Swings to Net Loss
Ticker: CTKB · Form: 10-Q · Filed: Aug 6, 2025 · CIK: 1831915
| Field | Detail |
|---|---|
| Company | Cytek Biosciences, Inc. (CTKB) |
| Form Type | 10-Q |
| Filed Date | Aug 6, 2025 |
| Risk Level | medium |
| Sentiment | bearish |
Sentiment: bearish
Topics: Biotechnology, Laboratory Instruments, Earnings Miss, Revenue Decline, Net Loss, Q2 2025, SEC Filing
Related Tickers: CTKB
TL;DR
**CTKB's Q2 numbers are a red flag; revenue dip and net loss mean it's time to re-evaluate your position.**
AI Summary
Cytek Biosciences, Inc. reported total revenue of $44.2 million for the three months ended June 30, 2025, a decrease from $46.5 million in the prior-year period. Product revenue for the quarter was $37.8 million, down from $40.2 million, while service revenue slightly increased to $6.4 million from $6.3 million. For the six months ended June 30, 2025, total revenue reached $87.1 million, a slight decrease from $87.4 million in the same period of 2024. The company experienced a net loss of $5.1 million for the second quarter of 2025, compared to a net income of $2.3 million in Q2 2024. This shift to a net loss is a significant change in profitability. Key business changes include a decrease in product sales, indicating potential market challenges or increased competition in the laboratory analytical instruments sector. The strategic outlook remains focused on innovation, but the immediate financial performance shows headwinds. Risks include continued revenue deceleration and the ability to return to profitability amidst a competitive landscape.
Why It Matters
Cytek Biosciences' Q2 2025 performance, marked by a revenue decline and a shift to a net loss, signals potential challenges for investors. This downturn could impact employee morale and future hiring, while customers might see increased pressure on product pricing or slower innovation if financial constraints tighten. In the competitive laboratory analytical instruments market, this financial weakening could allow rivals like BD Biosciences or Beckman Coulter to gain market share, potentially affecting Cytek's long-term position and the broader market's perception of growth in the sector.
Risk Assessment
Risk Level: medium — The risk level is medium due to the company's swing from a net income of $2.3 million in Q2 2024 to a net loss of $5.1 million in Q2 2025, coupled with a total revenue decrease from $46.5 million to $44.2 million in the same periods. This indicates a deteriorating financial performance and potential challenges in maintaining profitability and growth.
Analyst Insight
Investors should closely monitor Cytek's next earnings report for signs of stabilization or further decline. Consider reducing exposure if the trend of declining revenue and net losses persists, as competitive pressures appear to be impacting the company's financial health.
Financial Highlights
- revenue
- $44.2M
- net Income
- -$5.1M
- revenue Growth
- -4.9%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Product Revenue | $37.8M | -5.97% |
| Service Revenue | $6.4M | 1.59% |
Key Numbers
- $44.2M — Total Revenue (Q2 2025) (Decreased from $46.5M in Q2 2024, indicating a 4.9% decline.)
- -$5.1M — Net Income (Q2 2025) (Shifted from a $2.3M net income in Q2 2024 to a net loss, representing a significant profitability downturn.)
- $37.8M — Product Revenue (Q2 2025) (Down from $40.2M in Q2 2024, highlighting a core business segment decline.)
- $6.4M — Service Revenue (Q2 2025) (Slightly increased from $6.3M in Q2 2024, showing a minor positive trend in services.)
- $87.1M — Total Revenue (YTD 2025) (Slightly decreased from $87.4M in YTD 2024, indicating a flat to declining year-to-date performance.)
Key Players & Entities
- Cytek Biosciences, Inc. (company) — filer of the 10-Q
- BD Biosciences (company) — competitor in the laboratory analytical instruments market
- Beckman Coulter (company) — competitor in the laboratory analytical instruments market
- SEC (regulator) — recipient of the 10-Q filing
- $44.2 million (dollar_amount) — total revenue for Q2 2025
- $46.5 million (dollar_amount) — total revenue for Q2 2024
- $5.1 million (dollar_amount) — net loss for Q2 2025
- $2.3 million (dollar_amount) — net income for Q2 2024
- $37.8 million (dollar_amount) — product revenue for Q2 2025
- $40.2 million (dollar_amount) — product revenue for Q2 2024
FAQ
What were Cytek Biosciences' total revenues for the second quarter of 2025?
Cytek Biosciences, Inc. reported total revenue of $44.2 million for the three months ended June 30, 2025, which is a decrease from $46.5 million in the same period of 2024.
Did Cytek Biosciences achieve a net profit or loss in Q2 2025?
For the second quarter of 2025, Cytek Biosciences experienced a net loss of $5.1 million, a significant shift from the net income of $2.3 million reported in Q2 2024.
How did Cytek Biosciences' product revenue change in Q2 2025 compared to Q2 2024?
Product revenue for Cytek Biosciences decreased to $37.8 million in Q2 2025 from $40.2 million in Q2 2024, indicating a decline in core product sales.
What was the service revenue for Cytek Biosciences in the second quarter of 2025?
Cytek Biosciences' service revenue for the second quarter of 2025 was $6.4 million, showing a slight increase from $6.3 million in the comparable period of 2024.
What is the primary risk highlighted by Cytek Biosciences' Q2 2025 filing?
The primary risk highlighted is the company's inability to maintain profitability, evidenced by the swing from a net income of $2.3 million in Q2 2024 to a net loss of $5.1 million in Q2 2025, alongside declining total revenue.
What does the Q2 2025 filing suggest about Cytek Biosciences' competitive position?
The Q2 2025 filing suggests Cytek Biosciences may be facing increased competitive pressures, as evidenced by the decline in product revenue and overall revenue, potentially allowing competitors like BD Biosciences or Beckman Coulter to gain market share.
How might Cytek Biosciences' Q2 2025 results impact investors?
Investors might view Cytek Biosciences' Q2 2025 results negatively due to the revenue decline and net loss, potentially leading to a re-evaluation of their investment and consideration of reducing exposure if the negative trends continue.
What was Cytek Biosciences' total revenue for the first six months of 2025?
For the six months ended June 30, 2025, Cytek Biosciences reported total revenue of $87.1 million, a minor decrease from $87.4 million in the first six months of 2024.
Where is Cytek Biosciences' business address located?
Cytek Biosciences' business address is 47215 Lakeview Boulevard, Fremont, CA 94538.
What is the fiscal year end for Cytek Biosciences, Inc.?
The fiscal year end for Cytek Biosciences, Inc. is December 31.
Risk Factors
- Revenue Deceleration [high — market]: Total revenue for Q2 2025 was $44.2 million, a decrease from $46.5 million in the prior-year period. This 4.9% decline, driven by lower product revenue, signals potential market challenges or increased competition.
- Profitability Downturn [high — financial]: The company reported a net loss of $5.1 million for Q2 2025, a significant shift from a net income of $2.3 million in Q2 2024. This indicates a substantial deterioration in profitability.
- Competitive Landscape [medium — market]: The laboratory analytical instruments sector is competitive. A decline in product sales suggests Cytek may be facing increased pressure from competitors, impacting market share and pricing power.
Industry Context
Cytek Biosciences operates in the laboratory analytical instruments sector. This industry is characterized by technological innovation and a competitive landscape. Companies in this space often rely on strong product pipelines and robust service offerings to maintain market share and drive revenue growth.
Regulatory Implications
As a publicly traded company, Cytek Biosciences is subject to SEC regulations and reporting requirements, including the timely filing of 10-Q reports. Compliance with these regulations is crucial for maintaining investor confidence and market access.
What Investors Should Do
- Monitor competitive pressures and market share trends.
- Analyze the drivers of the shift to net loss.
- Evaluate the sustainability of service revenue growth.
Key Dates
- 2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q filing, showing a decrease in revenue and a shift to net loss.
- 2025-08-06: Filing Date of 10-Q — Public disclosure of the company's financial performance and condition for the period ended June 30, 2025.
Glossary
- 10-Q
- A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document contains the detailed financial information for Cytek Biosciences, Inc. for the second quarter of 2025.)
- Product Revenue
- Revenue generated from the sale of the company's core products, in this case, laboratory analytical instruments. (A key indicator of the company's primary business performance, which has seen a decline.)
- Service Revenue
- Revenue generated from services related to the company's products, such as maintenance, support, or training. (Represents a secondary revenue stream that showed slight growth, partially offsetting product revenue decline.)
Year-Over-Year Comparison
Compared to the prior year's second quarter, Cytek Biosciences reported a 4.9% decrease in total revenue, from $46.5 million to $44.2 million. The most significant change is the shift from a net income of $2.3 million in Q2 2024 to a net loss of $5.1 million in Q2 2025, indicating a substantial deterioration in profitability. No new significant risks were highlighted in the provided context compared to the previous period.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on August 6, 2025 regarding Cytek Biosciences, Inc. (CTKB).